Cadrenal Therapeutics, INC. 8-K Filing
Ticker: CVKD · Form: 8-K · Filed: Mar 31, 2026 · CIK: 0001937993
| Field | Detail |
|---|---|
| Company | Cadrenal Therapeutics, INC. (CVKD) |
| Form Type | 8-K |
| Filed Date | Mar 31, 2026 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Cadrenal Therapeutics, INC. (ticker: CVKD) to the SEC on Mar 31, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per share CVKD The Nasdaq Stock Mar).
How long is this filing?
Cadrenal Therapeutics, INC.'s 8-K filing is 2 pages with approximately 599 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 599 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2026-03-31 08:55:07
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CVKD The Nasdaq Stock Mar
Filing Documents
- ea0284258-8k_cadrenal.htm (8-K) — 27KB
- ea028425801ex99-1.htm (EX-99.1) — 52KB
- 0001213900-26-036937.txt ( ) — 250KB
- cvkd-20260331.xsd (EX-101.SCH) — 3KB
- cvkd-20260331_lab.xml (EX-101.LAB) — 33KB
- cvkd-20260331_pre.xml (EX-101.PRE) — 22KB
- ea0284258-8k_cadrenal_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On March 31, 2026, Cadrenal Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release that included financial information for the fiscal year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 99.1 Press Release, issued by Cadrenal Therapeutics, Inc. on March 31, 2026 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 31, 2026 CADRENAL THERAPEUTICS, INC. By: /s/ Quang X. Pham Name: Quang X. Pham Title: Chairman and Chief Executive Officer 2